Onxeo S.A. announced the formation of a new Scientific Advisory Committee of leading scientific and clinical experts in the fields of DDR, resistance to treatment and more globally, drug development in oncology. The Committee will advise and guide the Company as it advances its proprietary platform of compounds in the DDR field and develops innovative therapeutics that address unmet medical needs and improve the management of cancer patients. Scientific Advisory Committee include: Gilbert Chu; Gilles Favre; Lorenzo Galluzzi; Ruth Plummer; and Caroline Robert.